Standard Naloxone Prescribing for Palliative Care Cancer Patients on Opioid Therapy: A Single-Site Quality Improvement Pilot to Assess Attitudes and Access



      Limited data exist on when to offer naloxone to cancer patients on opioid therapy.


      We assessed patient and clinician attitudes on naloxone education (done via surveys at initial and follow up visits) and prescribing rates (via chart reviews) at a single ambulatory palliative care practice. Pharmacy records assessed naloxone dispense rates.


      During a three-month period, all new patients receiving opioid therapy were offered naloxone. Standardized educational materials on opioid safety and naloxone use were created and shared by clinical team.


      Naloxone prescribing rates increased from 5% to 66%. 92% (n = 23) of clinicians reported education/prescribing took ≤ five minutes, and 100% reported either a positive or neutral impact on the encounter. A total of 81% (n = 25) of patients reported no increased worry about opioid use, 68% (n = 21) felt safer with naloxone, and 97% rated the encounter as neutral or positive. 88% (n = 37) of prescriptions were dispensed and 67% of patients (n = 16) paid <$10.

      Conclusions/Lessons Learned

      Opioid safety education and naloxone prescribing can be done quickly and is well-received by clinicians and patients.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Pain and Symptom Management
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Kata V
        • Novitch MB
        • Jones MR
        • et al.
        Opioid addiction, diversion, and abuse in chronic and cancer pain.
        Curr Opin Support Palliat Care. 2018; 12: 124-130
        • Page R
        • Blanchard E
        Opioids and cancer pain: patients' needs and access challenges.
        J Oncol Pract. 2019; 15: 229-231
        • Carmichael AN
        • Morgan L
        • Del Fabbro E
        Identifying and assessing the risk of opioid abuse in patients with cancer: an integrative review.
        Subst Abuse Rehabil. 2016; 7: 71-79
        • Jairam V
        • Yang DX
        • Yu JB
        • Park HS
        Emergency department visits for opioid overdoses among patients with cancer.
        J Natl Cancer Inst. 2020; 112: 938-943
        • Gery P.
        Vital signs: pharmacy-based naloxone dispensing — United States, 2012–2018.
        in: US Department of Health and Human Services/Centers for Disease Control and Prevention: Morbidity and Mortality Weekly Report. 68. 2019
        • Chino F
        • Kamal A
        • Chino J.
        Incidence of opioid-associated deaths in cancer survivors in the United States, 2006-2016: a population study of the opioid epidemic.
        JAMA Oncol. 2020; 6: 1100-1102
        • Khan NF
        • Bateman BT
        • Landon JE
        • Gagne JJ
        Association of opioid overdose with opioid prescriptions to family members.
        JAMA Intern Med. 2019; 179: 1186-1192
        • Nguyen AP
        • Glanz JM
        • Narwaney KJ
        • Binswanger IA
        Association of opioids prescribed to family members with opioid overdose among adolescents and young adults.
        JAMA Netw Open. 2020; 3e201018
        • Meghani SH
        • Wool J
        • Davis J
        • et al.
        When patients take charge of opioids: self-management concerns and practices among cancer outpatients in the context of opioid crisis.
        J Pain Symptom Manage. 2020; 59: 618-625
      1. Katie Fitzgerald Jones ZS. How to screen for opioid use disorder and navigate complex opioid decisions. Case reviews web site. Published 2021. Accessed June 1, 2022.

        • Dowell D
        • Ragan KR
        • Jones CM
        • Baldwin GT
        • Chou R
        CDC clinical practice guideline for prescribing opioids for pain - United States, 2022.
        MMWR Recomm Rep. 2022; 71: 1-95
        • Mueller SR
        • Koester S
        • Glanz JM
        • Gardner EM
        • Binswanger IA
        Attitudes toward naloxone prescribing in clinical settings: a qualitative study of patients prescribed high dose opioids for chronic non-cancer pain.
        J Gen Intern Med. 2017; 32: 277-283
        • Paice JA
        • Portenoy R
        • Lacchetti C
        • et al.
        Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline.
        J Clin Oncol. 2016; 34: 3325-3345
        • Jairam V
        • Yang DX
        • Verma V
        • Yu JB
        • Park HS
        National patterns in prescription opioid use and misuse among cancer survivors in the United States.
        JAMA Netw Open. 2020; 3e2013605